NCT00004853 2019-11-12
Comparison of Filgrastim and Filgrastim SD/01in Boosting White Cell Counts After Intensive Chemotherapy
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
Clinical Trials
11 trialsNCT01416389 2019-09-18
A Study of LY2523355 in Participants With Breast Cancer
Eli Lilly and Company
Phase 2 Completed
NCT01214629 2018-08-06
A Study for Participants With Advanced Cancer
Eli Lilly and Company
Phase 1 Completed
NCT01214642 2018-08-06
A Dose-Escalation Study for Patients With Advanced Cancer
Eli Lilly and Company
Phase 1 Completed
NCT00911170 2017-12-29
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
Amgen
Phase 3 Completed
NCT00588094 2015-12-04
Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHL
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00115193 2013-08-29
Pegfilgrastim Administered on the Same Day as Chemotherapy in Non-Hodgkin's Lymphoma
Amgen
Phase 2 Completed
NCT00410696 2013-07-01
Pegfilgrastim Versus Filgrastim After High-dose Chemotherapy
Istituto Clinico Humanitas
Phase 2 Completed
NCT00050674 2012-12-27
Docetaxel and Gemcitabine With Filgrastim-SD/01 Support in Patients With Advanced Non-Small Cell Lung Carcinoma
Schwartzberg, Lee, M.D.
Phase 2 Completed
NCT00124111 2010-02-26
A Study of Cyclophosphamide/Methotrexate/5-Fluorouracil (CMF) With Pegfilgrastim in Subjects With Breast Cancer
Amgen
Phase 2 Completed
NCT00066092 2008-02-28
Pegfilgrastim PBPC Mobilization Study
Amgen
Phase 2 Completed